

TriMark Publications

August 2013
Volume: TMRBIOL13-0801

BIOLOGICS AND BIOSIMILARS WORLD MARKETS

(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	18	
1.1	Statement of this Report	18	
1.2	About this Report	18	
1.3	Scope of the Report	19	
1.4	Objectives	20	
1.5	Methodology	20	
1.6	Executive Summary	21	
2.	Pharmaceutical Industry: An Overview	23	
2.1	Global R&D Spending by Pharma and Biotech Companies	23	
2.1.1	Top 20 Companies in R&D Spending	24	
2.1.2	Top 20 Most Valuable Pharmaceutical R&D projects	24	
2.1.3	Most Valuable R&D Projects Ranked by Net Present Value	25	
2.2	FDA New Drug Approvals	26	
2.2.1	Top Ten NMEs	27	
2.3	Impact of Patent Expirations	27	
2.4	Immunity of Pharmaceutical Growth against Drop in GDP Growth	28	
2.5	Minimal Annual Growth Rates of Pharmaceuticals in Developed Markets	29	
2.6	Falling Operating Profit Rate for Big Pharma	30	
2.7	Top Ten Global Pharmaceutical Firms	30	
2.6	Top Ten Pharmaceuticals by Sales Revenue	32	
2.7	Worldwide Prescription and OTC Sales by Therapy Area in 2018	33	
2.8	Top Companies in Oncology Sales	34	
2.8.1	Top Five Oncology Products	35	
2.9	Top Companies in Anti-Diabetes Market	36	
2.9.1	Top Five Anti-Diabetes Products	36	
2.10	Top Ten Companies in Anti-Rheumatics Market	37	
2.10.1	Top Ten Anti-Rheumatics Products	37	
2.11	Top Ten Vaccine Companies and Global Sales	38	
2.11.1	Top Five Vaccine Products	38	
2.12	Top Ten Anti-Viral Companies	39	
2.12.1	Top Five Anti-Viral Products	39	
2.13	Top 50 Global Pharmaceutical Brands in 2018	40	
2.14	M&A Transactions in 2012	41	
2.15	Global Pharmaceutical Market	42	
2.15.1	Global Pharmaceutical Sales by Region	43	
2.15.2	North American Pharmaceutical Market	44	
2.15.2.1	U.S. Prescription Drug Sales by Company	45	
2.15.2.2	Top 50 Pharmaceutical Products in the U.S.	46	
2.15.2.3	Top 50 Products in the U.S. in 2018	48	
2.15.3	Pharmaceutical Market in Europe	49	
2.15.3.1	European Prescription Drug Sales by Company	50	
2.15.4	Pharmaceutical Market in Asia/Pacific	52	
2.15.4.1	Prescription Drug Sales in Japan by Company	53	
2.15.5	Pharmaceutical Market in Latin America	54	
2.15.6	Pharmaceutical Market in Africa	55	
2.15.7	Pharmaceutical Market in the Middle East	56	
2.16	Regional Prescription Drug Sales in the U.S., Europe and Japan	57	
2.17	Global Prescription Drug Sales	58	
3.	Brand Name Pharmaceuticals: A Brief Overview	59	
3.1	Birth Pangs and Life Span of Branded Drugs	59	
3.2	Major Patent Expiries of Branded Drugs	60	
3.3	Global Market for Branded Drugs	61	
3.4	Increasing R&D Pipeline	62	
3.4.1	The 2012 R&D Pipeline by Phase	63	

3.4.2	Top Companies by Pipeline Size	64	
3.4.3	Total Number of Companies with Active R&D	65	
3.4.4	Global Distribution of Companies Active in Pharma R&D	66	66
3.4.5	Top Therapy Areas in R&D	67	
3.4.5.1	Top 25 Individual Diseases in the R&D Pipeline	68	
3.4.6	Top 20 Mechanism of Action in R&D Pipeline	69	
3.4.7	Top 25 Drug Protein Targets	70	
4.	Generic Drugs: A Brief Overview	72	
4.1	Bioequivalence of Generics	72	
4.2	Global Market for Generics	73	
4.3	Operating Profit Rate for Generic Companies	74	
4.4	Outsourced Manufacture of Generics	75	
4.5	Generic Utilization in International Markets	76	
4.6	Global Generic Sales by Company	77	
5.	Biologics	79	
5.1	Regulations for Biologics	79	
5.2	Complexity of Biologics	80	
5.3	Concentration of Global Biopharmaceutical Manufacturing	80	80
5.4	Number of Biologics Available in the Global Market	82	
5.5	Share of Biologics by Country/Region	82	
5.6	Rate of Growth for Biologics by Region	83	
5.6.1	Growth Rates of APIs and Biologics Compared	84	84
5.7	Manufacturing Capacity of Biologics	85	
5.8	Biologics Market by Segment	85	
5.9	Patent Expiry for Biologic Drugs	86	
5.9.1	India's Opportunity from Biologic Patent Expirations	87	87
5.10	Major Players in Biologics	88	
5.11	Biopharmaceutical Outsourcing	89	
5.12	Top 20 Biologics by Sales	90	
5.12.1	Roche's Biologics Arsenal	91	
5.12.2	Johnson & Johnson's Biologics Arsenal	92	
5.12.3	Lonza in Biologics	92	
5.13	The Best Selling Biologics by Class	92	
5.14	Biologic Drugs: Market Trends in the Past Seven Years	93	93
5.14.1	Global Market for Biologics	94	
5.15	Global and U.S. Sales of Blockbuster Biologics	95	
5.15.1	Global Market for Humira	95	
5.15.1.1	Humira (Adalimumab) Pen's Market by Geography	95	
5.15.1.2	U.S. Sales of Humira	96	
5.15.1.3	The Leader among Biologics	97	
5.15.2	Global Market for Remicade	97	
5.15.2.1	Remicade's Market by Geography	98	
5.15.2.2	U.S. Sales of Remicade	99	
5.15.3	Global Market for Enbrel	100	
5.15.3.1	Enbrel's Market by Geography	100	
5.15.3.2	U.S. Sales of Enbrel	101	
5.15.4	Global Market for Simponi	102	
5.15.5	Global Market for Tysabri	103	
5.15.5.1	U.S. Market for Tysabri	104	
5.15.6	Global Market for Lantus	104	
5.15.6.1	Lantus' Market by Geography	105	
5.15.6.2	U.S. Market for Lantus	106	
5.15.7	Global Market for NovoRapid	106	
5.15.7.1	Market for NovoLog/NovoRapid by Geography	107	107
5.15.7.2	U.S. Market for NovoRapid	108	
5.15.8	Global Market for Victoza	108	

5.15.9	Global Market for Levemir	110
5.15.9.1	U.S. Market for Levemir	111
5.15.10	Global Market for Humalog	111
5.15.10.1	Market for Humalog by Geography	113
5.15.11	Global Market for Neulasta	113
5.15.11.1	Neulasta's Market by Geography	114
5.15.11.2	U.S. Market for Neulasta	115
5.15.12	Global Market for Privigen	115
5.15.13	Global Market for Perjeta	116
5.15.14	Global Market for Xgeva/Prolia	117
5.15.15	Global Market for Soliris	119
5.15.15.1	U.S. Market for Soliris	120
5.15.16	Global Market for Botox	120
5.15.17	Global Market for Lucentis	122
5.15.17.1	U.S. Market for Lucentis	123
5.15.18	Global Market for Eylea	123
5.15.19	Global Market for Avastin	125
5.15.19.1	U.S. Market for Avastin	126
5.15.20	Global Market for Rituxan	126
5.15.20.1	Rituxan's Market by Geography	127
5.15.20.2	U.S. Market for Rituxan	128
5.15.21	Global Market for Revlimid	128
5.15.22	Global Market for Herceptin	130
5.15.22.1	Herceptin's Market by Geography	130
5.15.22.2	U.S. Market for Herceptin	131
5.15.23	Global Market for Prevnar	132
5.15.23.1	U.S. Market for Prevnar	133
5.15.24	Global Market for Gardasil	133
5.15.25	Global Market for Fluzone/Varigrip	135
5.15.26	Global Market for Varivax	135
5.15.27	Global Market for Stelara	137
5.15.27.1	U.S. Market for Stelara	138
5.15.28	Global Market for Actemra	138
5.15.29	Global Market for Gammagard Liquid	139
5.16	The U.S. Biotech Landscape	141
5.16.1	Top U.S. Biotech Companies	141
5.16.1.1	Amgen	141
5.16.1.2	Gilead Sciences	142
5.16.1.3	Biogen Idec, Inc.	143
5.16.1.4	Celgene Corporation	144
5.16.1.5	Genzyme (Sanofi)	144
5.16.1.6	Life Technologies Corporation	145
5.16.1.7	Cephalon, Inc./Teva Pharmaceutical Industries Ltd.	145
5.16.1.8	Alexion Pharmaceuticals, Inc.	145
5.16.1.9	Cubist Pharmaceuticals, Inc.	145
5.16.1.10	United Therapeutics Corporation	146
5.16.2	Overall Performance of the U.S. Biotech Companies	146
5.16.3	R&D Spending by Biotech Companies in the U.S.	146
5.16.4	U.S. Market for Biologic Drugs	147
5.16.5	The Leading Biologic Drug Classes in Terms of U.S. Sales	148
5.16.5.1	Top Selling Biologic Drugs in the U.S.	149
5.16.5.2	U.S. Sales of Biologics by Manufacturer	150
5.16.6	U.S. Sales of mAbs	151
5.16.7	U.S. Sales of Recombinant Hormones	152
5.16.8	U.S. Sales of Blood Cell Growth Factors	153
5.16.9	U.S. Market for Cytokines	154
5.16.10	U.S. Sales of Blood Factors	155
5.16.11	U.S. Sales of Therapeutic Enzymes	156

5.16.12	U.S. Sales of Recombinant Vaccines	157
5.16.13	U.S. Sales of Recombinant Anticoagulants	157
5.16.14	Costs of Commonly Used Biologicals in the U.S.	158
5.16.15	Biologics Used for Treating Rheumatoid Arthritis	159
5.16.15.1	Cost Comparison of Arthritis Biologics	160
5.17	Biologics in Europe	160
5.17.1	Uptake of Biologics in Europe by Drug Type	161
5.17.2	European Market for mAbs	162
5.18	Biologics in Hemophilia	163
5.18.1	Marker Leaders in Hemophilia	164
5.18.2	Hemophilia A	164
5.18.3	Hemophilia B	165
5.18.4	Inhibitors	166
6.	Biosimilars	168
6.1	Different Names in Different Countries for Biologics	168
6.2	E.U. Approval Pathway for Biosimilars	168
6.3	Contentious Issues in Biosimilars	168
6.4	Biosimilars Opportunity	168
6.5	Challenges in Biosimilar Introduction	169
6.6	Production and Market Access of Biosimilars	169
6.7	Country Selection for Biosimilars	169
6.8	High Barriers to the Entry of Biosimilars	169
6.9	Global Competition among Biosimilars	170
6.10	Definitions and Interpretations of Biosimilar Products	171
6.10.1	Regulatory Requirements	171
6.10.1.1	World Health Organization	171
6.10.1.2	Key Principles and Basic Concept	172
6.10.2	Reference Biotherapeutic Product	172
6.10.2.1	Quality	172
6.10.2.2	Non-Clinical and Clinical Studies	172
6.10.3	E.U.	173
6.10.3.1	Key Principles and Basic Concept	173
6.10.3.2	Reference Biotherapeutic Product	174
6.10.3.3	Quality	174
6.10.3.4	Non-Clinical and Clinical Evaluation	174
6.10.3.5	Product Class-Specific Guidelines	174
6.10.4	U.S.	175
6.10.5	Canada	176
6.10.6	Japan	176
6.10.7	Korea	176
6.11	FDA Guidelines for Biosimilars	177
6.12	Market Drivers	177
6.12.1	Cost Pressures	177
6.13	Core Therapy Areas for Biosimilars	177
6.14	Competitive Landscape in Biosimilar Sector	178
6.15	Opportunities for Biosimilars in Three Geographies	179
6.15.1	Opportunities for Biosimilars in the U.S.	180
6.15.2	European Opportunities for Biosimilars	180
6.15.3	Opportunities for Biosimilars in Emerging Markets	180
6.16	Biosimilar Experience	181
6.17	Development of Biosimilars	182
6.17.1	Current and Future Trends in Biosimilar Development	182
6.18	Top Players in Biosimilars Market	183
6.18.1	Other Key Players in Biosimilars Market	185
6.19	Number of Biologics Patent Expiries Prior to 2020	186
6.19.1	Biologics Patent Expiries by Region	187
6.20	Monoclonal Antibodies: The Key Focus Area for Biosimilars Development	188

6.20.1	Biosimilar mAbs in Pipeline	188
6.20.2	Disease Indications for Biosimilar mAbs	190
6.21	Global Leaders in Biosimilars	191
6.22	Market Leading Biosimilars	191
6.23	Biosimilar Opportunities: Only for the Heartiest Biotech Firms	192
6.24	Biosimilars Pipeline by Class	193
6.25	Global Biosimilars Market	193
6.25.1	Estimated Value and Growth Rates for Biosimilars by Type	194
6.25.2	Market Leading Biosimilars in 2015	196
6.26	Regulations for Biosimilars in the U.S.	196
6.26.1	BPCIA and Guidance	197
6.26.2	Scientific Considerations	197
6.26.3	Quality Considerations	197
6.26.4	Biosimilar User Fee Act	197
6.26.5	12-Year Exclusivity Period	198
6.26.6	Biosimilars Competitive Landscape in the U.S.	199
6.26.7	Manufacturing Capabilities	199
6.26.8	Clinical Trial Experience	200
6.26.9	Market Experience	201
6.26.10	Likely Early Entrants	201
6.26.11	Recombinant Protein Competition	202
6.26.12	mAbs Competition	202
6.27	U.S. Biosimilars Market	203
6.27.1	HGH Biosimilars in the U.S. Market	204
6.27.2	Cost Benefits from Biosimilars for U.S. Healthcare	205
6.27.3	Development Pipeline and Market Evolution of Biosimilars in the U.S.	206
6.27.3.1	Target Reference Products	207
6.27.3.2	Launchable Dates for Biosimilars in the U.S.	207
6.27.3.3	Number of Biosimilar Products in the Pipeline	209
6.28	Geographic Distribution of Biosimilars Pipeline	210
6.28.1	Developers of Biosimilars	211
6.29	Future of U.S. Biosimilars Market	214
6.29.1	Future Pricing Models	214
6.29.2	Future Price Reduction and the Profit Margin	214
6.30	Biosimilars Market in Europe and Japan	215
6.30.1	The Instant Growth of Biosimilars in Europe	216
6.30.2	Biosimilar mAbs on the Horizon in Europe	217
6.30.3	Biosimilars Approved in the E.U	218
6.30.4	Utilization of G-CSF in Europe	219
6.31	Revenue Forecast for Biosimilar Insulins	220
6.32	Revenue Forecast for Biosimilar HGH	221
6.33	Revenue Forecast for Biosimilar IFN Alpha	222
6.34	Revenue Forecast for Biosimilar IFN Beta 1a	222
6.35	Revenue Forecast for Biosimilar Filgrastim	223
6.36	Revenue Forecast for Biosimilar Epoetin Alpha	224
6.37	Uptake of Biosimilars in Europe	224
6.38	Biosimilars in China	225
6.38.1	Biosimilars Sales in China	226
6.39	Indian Market for Biosimilars	228
6.39.1	Domestic Biosimilar Developers in India	228
6.40	Biosimilar Pipeline of Celltrion in Korea	229
6.41	Deals in Biosimilar Space	230
6.41.1	Technologies	230
6.41.2	Manufacturing Agreements	230
6.41.3	Clinical Development	231
6.41.4	Licensing Agreements	231
6.42	Transactions in Biosimilars Industry	231
6.42.1	Biosimilars Market: Opportunities and Challenges	232

6.42.2	Recent Transactions in Biosimilars Industry	233
6.43	Top Ten Biosimilar Drugs to Watch	234
6.43.1	Aranesp (Darbepoetin Alfa)	234
6.43.2	Enbrel (Etanercept)	235
6.43.3	Epogen/Procrit/Epex/Erypo (Epoetin Alfa)	235
6.43.4	Genotropin (Somatropin)	236
6.43.5	Herceptin (Trastuzumab)	236
6.43.6	Humira (Adalimumab)	236
6.43.7	Neulasta (Pegfilgrastim)	237
6.43.8	Neupogen (Filgrastim)	237
6.43.9	Remicade (Infliximab)	238
6.43.10	Rituxan/MabThera (Rituximab)	238
7.	Company Profiles	240
7.1	3Bio, Inc.	240
7.1.1	EPIAO	240
7.1.2	TPIAO	240
7.1.3	INTEFEN	241
7.1.4	INLEUSIN	241
7.1.5	IV Iron Sucrose	242
7.2	Abbott Laboratories	242
7.3	AbbVie, Inc.	243
7.3.1	Products	244
7.4	Actelion Ltd.	244
7.5	Amgen, Inc.	245
7.5.1	Neulasta (Filgrastim)	245
7.5.2	Enbrel (Etanercept)	245
7.5.3	Aranesp (Darbepoetin Alfa)	245
7.5.4	Epogen (Epoetin Alfa)	245
7.5.5	Sensipar/Mimpara (Cinacalcet)	245
7.5.6	Vectibix (Panitumumab)	246
7.5.7	Nplate (Romiplostim)	246
7.5.8	Prolia/Xgeva (Denosumab)	246
7.6	Amoytop Biotech Co., Ltd	246
7.6.1	Molgramostim (rhGM-CSF)	246
7.6.2	Filgrastim (rh G-CSF)	247
7.6.3	Oprelvekin (rhIL-11)	247
7.7	Anhui Anke Biotechnology (Group) Co., Ltd.	247
7.7.1	Anterferon Alpha 2b Injection	248
7.7.2	Ansomone	248
7.7.3	Anterferon Alpha 2b Cream	248
7.7.4	Anterferon alpha 2b Eyedrop	248
7.8	Apotex, Inc.	248
7.9	Astellas Pharma, Inc.	249
7.10	AstraZeneca	250
7.10.1	AstraZeneca's R&D Portfolio	250
7.10.2	Patent Expiries of AstraZeneca's Products	251
7.11	Bayer AG	251
7.12	Beijing Four Rings Biopharmaceuticals	252
7.12.1	Products	252
7.13	Bharat Serums and Vaccines Limited	252
7.14	Biocon Ltd.	253
7.15	Biogen Idec, Inc.	255
7.16	Bioton SA	256
7.17	Boehringer Ingelheim Pharmaceuticals, Inc.	257
7.18	Bristol-Myers Squibb, Co.	258
7.19	Celgene Corporation	259
7.20	Celltrion, Inc.	259

7.20.1	Technology Overview	259
7.20.2	Biosimilars Development	259
7.20.3	Contract Manufacturing	259
7.21	Cipla Ltd.	260
7.21.1	Cipla's Prescription Product Category	260
7.22	Dr. Reddy's Laboratories Ltd.	261
7.23	Elan Corporation, PLC	262
7.23.1	Tysabri	262
7.24	Eli Lilly & Co.	263
7.25	Gideon Richter	263
7.26	Gilead Sciences, Inc.	264
7.27	GlaxoSmithKline PLC	265
7.28	Hospira, Inc.	267
7.29	Intas Pharmaceuticals Limited	268
7.30	Johnson & Johnson	268
7.31	Merck & Co., Inc.	269
7.32	Mylan, Inc.	270
7.32.1	Mylan's Generics	271
7.32.2	Mylan's Active Pharmaceutical Ingredients	271
7.32.3	Mylan's Specialty	271
7.32.4	Mylan's Anti-Retroviral Franchise	271
7.33	Novartis AG	271
7.34	Pfizer, Inc.	273
7.35	Roche Holdings AG	274
7.36	Sandoz International GmbH	276
7.37	Sanofi	276
7.38	Stada Arzneimittel Aktiengesellschaft	278
7.39	Teva Pharmaceutical Industries Limited	279
7.40	Watson Pharmaceuticals, Inc.	280

APPENDIX

Appendix 1:	Biologic Medicines by Development Phase	281
Appendix 2:	Declining Medicine Use in the U.S.	305
Appendix 2.1:	Changes in Utilization	305
Appendix 2.2:	Healthcare Costs and Spending on Medicines	306
Appendix 2.3:	Total Spending on Medicines	309
Appendix 2.4:	Transformations in Disease Treatment	319
Appendix 2.5:	Key Breakthrough Therapies Approved in 2012	322
Appendix 2.5.1:	Cystic Fibrosis: Ivacaftor (Kalydeco)	322
Appendix 2.5.2:	Rheumatoid Arthritis: Tofacitinib (Xeljanz)	323
Appendix 2.5.3:	Basal-Cell Carcinoma: Vismodegib (Erivedge)	323
Appendix 2.5.4:	Irritable Bowel Syndrome with Constipation: Linaclotide (Linzess)	323
Appendix 2.5.5:	HIV: Emtricitabine and Tenofovir Disoproxil Fumarate (Truvada)	323
Appendix 2.5.6:	Combination of Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Disoproxil Fumarate	323
Appendix 2.6:	Spending in Major Therapies	323
Appendix 2.6.1:	Oncology Spending (\$25.9 Billion) by Area, 2012	324
Appendix 2.6.1.1:	U.S. Market for Oncology Drugs	325
Appendix 2.6.1.2:	U.S. Market for Rituxan	326
Appendix 2.6.1.3:	U.S. Market for Avastin	327
Appendix 2.7:	Mental Health Spending by Area	327
Appendix 2.7.1:	U.S. Market for Mental Health Drugs	328
Appendix 2.7.2:	U.S. Market for Cymbalta	329
Appendix 2.7.3:	U.S. Market for Abilify	330
Appendix 2.8:	Respiratory Spending by Area	331
Appendix 2.8.1:	U.S. Market for Respiratory Drugs	332
Appendix 2.8.2:	U.S. Market for Advair	333

Appendix 2.8.3: U.S. Market for Singulair	334
Appendix 2.8.4: U.S. Market for Spiriva	335
Appendix 2.9: Antidiabetes Spending by Area	335
Appendix 2.9.1: U.S. Market for Antidiabetics	336
Appendix 2.9.2: U.S. Market for Januvia	337
Appendix 2.9.3: U.S. Market for Lantus	338
Appendix 2.9.4: U.S. Market for Lantus SoloSTAR	339
Appendix 2.10: Pain Spending by Area	341
Appendix 2.10.1: U.S. Market for Pain Management Drugs	341
Appendix 2.11: U.S. Market for Medicines Used in Nervous System Disorders	342
Appendix 2.11.1: U.S. Market for Oxycontin	343
Appendix 2.11.2: U.S. Market for Lyrica	343
Appendix 2.11.3: U.S. Market for Copaxone	344
Appendix 2.12: U.S. Market for Lipid Regulators	345
Appendix 2.12.1: U.S. Market for Crestor	346
Appendix 2.13: U.S. Market for Autoimmune Drugs	346
Appendix 2.13.1: U.S. Market for Humira	347
Appendix 2.13.2: U.S. Market for Enbrel	348
Appendix 2.13.3: U.S. Market for Remicade	349
Appendix 2.14: U.S. Market for Medicines Used for Multiple Sclerosis	350
Appendix 2.15: U.S. Market for Antiulcerants	351
Appendix 2.15.1: U.S. Market for Nexium	352
Appendix 2.16: U.S. Market for Neulasta	352
Appendix 2.17: U.S. Market for Epogen	353
Appendix 2.18: U.S. Market for Platelet Aggregation Inhibitors	354
Appendix 2.18.1: U.S. Market for Plavix	355
Appendix 2.19: U.S. Market for HIV Antivirals	355
Appendix 2.19.1: U.S. Market for Atripla	356
Appendix 2.19.2: U.S. Market for Truvada	357
Appendix 2.20: U.S. Market for Antibacterials	358
Appendix 2.21: U.S. Market for Antihypertensives	359
Appendix 2.21.1: U.S. Market for Diovan	359
Appendix 2.22: U.S. Market for ADHD	360
Appendix 2.23: U.S. Market for Vaccines (Pure, Comb and Others)	361
Appendix 2.24: U.S. Market for Systemic Hormonal Contraceptives	362
Appendix 2.25: Number of Treated Patients in Selected Therapies in the U.S.	363
Appendix 2.26: Top Therapeutic Classes of Drugs Prescribed in the U.S.	363
Appendix 2.27: Top Medicines Prescribed in the U.S.	365
Appendix 3: Pharma Deals in 2012	367
Appendix 4: Pharma Outsourcing in Asia	370
Appendix 4.1: Cluster One: Pharma Revenue Constraints	370
Appendix 4.2: Cluster Two: Asia Growth Forces	370
Appendix 4.3: Cluster Three: East/West Convergence/Divergence Trends	371
Appendix 4.4: Cluster Four: Technological/Business Model Forces	372
Appendix 4.5: Implications of the Four Clusters for Asia Outsourcing	372
Appendix 4.5.1: Rapid Expansion of Clinical Trials in Asia	373
Appendix 4.5.2: Manufacturing Scales	373
Appendix 4.5.3: Risk and Opportunity Overview	373
Appendix 4.5.4: Cost Ranking of Asian Territories	374
Appendix 4.5.5: Market Opportunity Ranking	375
Appendix 4.6: Outsourcing Hot Spots in Asia	376
Appendix 4.6.1: China	376
Appendix 4.6.2: India	378
Appendix 4.6.3: Singapore	379
Appendix 5: The Changing Payment Landscape for the U.S. Pharmaceutical Industry	381
Appendix 5.1: The Impetus for Defining Value	381
Appendix 5.1.1: Force I	381
Appendix 5.1.2: Force II	382

Appendix 5.1.3: Force III	383
Appendix 5.1.4: Force IV	384
Appendix 5.1.5: Force V	385
Appendix 5.2: The New Arbiters of Value	386
Appendix 5.2.1: Prescribers Looking for Value	386
Appendix 5.2.2: More Investment in Comparative Effectiveness Research	387
Appendix 5.2.3: Unleashing of Imprisoned Value	387
Appendix 5.2.4: Role of Companion Diagnostics	388
Appendix 5.2.5: Outcomes-Dependent Contracts	389
Appendix 5.2.6: Data-Sharing Agreements	391
Appendix 5.2.7: Patient-Reported Outcomes	392
Appendix 5.2.8: Evidence Needed to Secure Formulary Slots	393
Appendix 6: Medical Cost Trend in the U.S., 2013	394
Appendix 6.1: The Components of Medical Cost	394
Appendix 6.2: Leading Factors in Setting Insurance Premiums	395
Appendix 6.3: Factors Affecting 2013 Trend	395
Appendix 6.3.1: Medical Supply and Equipment Cost	395
Appendix 6.3.2: Newer Delivery Methods for Primary Care	396
Appendix 6.4: Uptick in Utilization and Expensive Advances	397
Appendix 6.4.1: Economic Utilization and Economic Growth	397
Appendix 6.4.2: Medical Advances Driving Growth	397
Appendix 6.4.3: The “New Normal”	399
Appendix 6.4.4: Current Practices by Employers	400
Appendix 6.4.4.1: Things to be considered by Employers	400
Appendix 6.5: Current Practices by Providers	401
Appendix 6.5.1: Things to be considered by Providers	401
Appendix 6.6: Current Practices by Health Insurers	401
Appendix 6.6.1: Things to be considered by Health Insurers	401
Appendix 6.7: Current Practices by Pharmaceutical and Life Sciences	402
Appendix 6.7.1: Things to be considered by Pharmaceutical and Life Sciences	402
Appendix 7: Naming of Drug Molecules and Pharmaceutical Brands	403
Appendix 7.1: Names of a Drug	403
Appendix 7.1.1: Chemical Name	403
Appendix 7.1.2: Generic Name	403
Appendix 7.2: Brand Name	404
Appendix 7.2.1: Criteria for Brand Names	405
Appendix 7.3: Stories behind Some Blockbuster Molecules	406

INDEX OF FIGURES

Figure 2.1: Global R&D Spending by Pharma and Biotech Companies, 2005-2018	23
Figure 2.2: Worldwide Sales at Risk by Patent Expiration, 2004-2018	28
Figure 2.3: Immunity of Pharmaceutical Growth against Drop in GDP Growth	29
Figure 2.4: Falling Operating Profit Rate for Big Pharma	30
Figure 2.5: Global Pharmaceutical Market, 2012-2019	43
Figure 2.6: Global Pharmaceutical Sales by Region	43
Figure 2.7: North American Pharmaceutical Market, 2012-2019	44
Figure 2.8: European Pharmaceutical Market, 2012-2019	50
Figure 2.9: Pharmaceutical Market in Asia/Pacific, 2012-2019	52
Figure 2.10: Pharmaceutical Market in Latin America, 2012-2019	55
Figure 2.11: Pharmaceutical Market in Africa, 2012-2019	56
Figure 2.12: Pharmaceutical Market in the Middle East, 2012-2019	57
Figure 2.13: Worldwide Total Prescription Drug Sales, 2004-2018	58
Figure 3.1: The Long-Drawn R&D Process for Branded Drugs	60
Figure 3.2: Global Market for Branded Drugs, 2012-2019	62
Figure 3.3: R&D pipeline, 2001-2012	63
Figure 3.4: R&D Pipeline by Phase, 2007-2012	64

Figure 3.5: Total Number of Companies with Active R&D, 2000-2012	66
Figure 3.6: Global Distribution of Companies Active in Pharma R&D, 2012	67
Figure 4.1: Differences between Originals and Copies (Branded/Generics & Biologics/Biosimilars)	72
Figure 4.2: Global Market for Generics, 2012-2019	74
Figure 4.3: Operating Profit Rate for Top Six Generic Companies, 2006-2012	75
Figure 4.4: Outsourced Manufacturing of Generics by Region/Country	76
Figure 4.5: Generic Drug Use in International Markets	77
Figure 5.1: The Biologic Drug Development Process	79
Figure 5.2: Comparison of Small Molecule Drugs and Biologics	80
Figure 5.3: Concentration of Global Biopharmaceutical Manufacturing as of 2013	81
Figure 5.4: Share of Biologics Sales by Country/Region	83
Figure 5.5: Rate of Growth for Biologics by Region	84
Figure 5.6: Growth Rates (CAGR) of APIs and Biologics Compared	84
Figure 5.7: Global Installed Biopharmaceutical Manufacturing Capacity by Top Ten Companies	85
Figure 5.8: Biologics Market by Segment	86
Figure 5.9: Top Biologics Losing Patent Protection and Market Exclusivity Prior to 2018	87
Figure 5.10: Global Value and Number of Biologic Drugs Losing Patent Protection, 2010-2015	88
Figure 5.11: Top Ten Biopharmaceuticals Manufacturing Companies	88
Figure 5.12: Outsourcing Trends in Biological Production across All Cell-Based Platforms	89
Figure 5.13: The Largest Selling Biologics by Class, 2012	92
Figure 5.14: Global Biologic Drugs Market Trends, 2006-2012	93
Figure 5.15: Global Market for Biologics, 2010-2020	94
Figure 5.16: Global Market for Humira, 2012-2019	95
Figure 5.17: Humira Pen's Market by Geography	96
Figure 5.18: U.S. Market for Humira, 2012-2019	96
Figure 5.19: Global Market for Remicade, 2012-2019	98
Figure 5.20: Remicade's Market by Geography	99
Figure 5.21: U.S. Market for Remicade, 2012-2019	99
Figure 5.22: Global Market for Enbrel, 2012-2019	100
Figure 5.23: Enbrel's Market by Geography	101
Figure 5.24: U.S. Market for Enbrel, 2012-2019	101
Figure 5.25: Global Market for Simponi, 2012-2019	102
Figure 5.26: Global Market for Tysabri, 2012-2019	103
Figure 5.27: U.S. Market for Tysabri, 2012-2019	104
Figure 5.28: Global Market for Lantus, 2012-2019	105
Figure 5.29: Lantus' Market Share by Geography	105
Figure 5.30: U.S. Market for Lantus, 2012-2019	106
Figure 5.31: Global Market for NovoRapid, 2012-2019	107
Figure 5.32: Market for NovoLog/NovoRapid by Geography	107
Figure 5.33: U.S. Market for NovoRapid, 2012-2019	108
Figure 5.34: Global Market for Victoza, 2012-2019	109
Figure 5.35: U.S. Market for Victoza, 2012-2019	109
Figure 5.36: Global Market for Levemir, 2012-2019	110
Figure 5.37: U.S. Market for Levemir, 2012-2019	111
Figure 5.38: Global Market for Humalog, 2012-2019	112
Figure 5.39: U.S. Market for Humalog, 2012-2019	112
Figure 5.40: Humalog's Market by Geography	113
Figure 5.41: Global Market for Neulasta, 2012-2019	114
Figure 5.42: Neulasta's Market Share by Geography	114
Figure 5.43: U.S. Market for Neulasta, 2012-2019	115
Figure 5.44: Global Market for Privigen, 2012-2019	116
Figure 5.45: Global Market for Perjeta, 2012-2019	117
Figure 5.46: Global Market for Xgeva/Prolia, 2012-2019	118
Figure 5.47: U.S. Market for Xgeva/Prolia, 2012-2019	118
Figure 5.48: Global Market for Soliris, 2012-2019	119
Figure 5.49: U.S. Market for Soliris, 2012-2019	120
Figure 5.50: Global Market for Botox, 2012-2019	121
Figure 5.51: U.S. Market for Botox, 2012-2019	121

Figure 5.52: Global Market for Lucentis, 2012-2019	122
Figure 5.53: U.S. Market for Lucentis, 2012-2019	123
Figure 5.54: Global Market for Eylea, 2012-2019	124
Figure 5.55: U.S. Market for Eylea, 2012-2019	124
Figure 5.56: Global Market for Avastin, 2012-2019	125
Figure 5.57: U.S. Market for Avastin, 2012-2019	126
Figure 5.58: Global Market for Rituxan, 2012-2019	127
Figure 5.59: Rituxan's Market Share by Geography	127
Figure 5.60: U.S. Market for Rituxan, 2012-2019	128
Figure 5.61: Global Market for Revlimid, 2012-2019	129
Figure 5.62: U.S. Market for Revlimid, 2012-2019	129
Figure 5.63: Global Market for Herceptin, 2012-2019	130
Figure 5.64: Herceptin's Market Share by Geography	131
Figure 5.65: U.S. Market for Herceptin, 2012-2019	131
Figure 5.67: Global Market for Prevnar 13, 2012-2019	132
Figure 5.68: U.S. Market for Prevnar 13, 2012-2019	133
Figure 5.69: Global Market for Gardasil, 2012-2019	134
Figure 5.70: U.S. Market for Gardasil, 2012-2019	134
Figure 5.71: Global Market for Fluzone/Varigrip, 2012-2019	135
Figure 5.72: Global Market for Varivax, 2012-2019	136
Figure 5.73: U.S. Market for Varivax, 2012-2019	136
Figure 5.74: Global Market for Stelara, 2012-2019	137
Figure 5.75: U.S. Market for Stelara, 2012-2019	138
Figure 5.76: Global Market for Actemra, 2012-2019	139
Figure 5.77: Global Market for Gammagard Liquid, 2012-2019	140
Figure 5.78: U.S. Market for Gammagard Liquid, 2012-2019	140
Figure 5.79: U.S. Market for Biologic Drugs, 2007-2012	148
Figure 5.80: The Leading Biologic Drug Classes in Terms of U.S. Sales	149
Figure 5.81: Top Selling Biologic Drugs in the U.S.	150
Figure 5.82: U.S. Sales of Biologics by Manufacturer	151
Figure 5.83: U.S. Sales of mAbs	152
Figure 5.84: U.S. Sales of Recombinant Hormones	152
Figure 5.85: U.S. Sales of Blood Cell Growth Factors	154
Figure 5.86: U.S. Sales of Cytokines	155
Figure 5.87: U.S. sales of Blood Factors	156
Figure 5.89: U.S. Sales of Therapeutic Enzymes	156
Figure 5.90: U.S. Sales of Recombinant Vaccines	157
Figure 5.91: U.S. Sales of Recombinant Anticoagulants	158
Figure 5.92: Market for Biologics in Europe, 2012-2019	161
Figure 5.93: Uptake of Biologics in Europe by Drug Type	162
Figure 5.94: European Market for mAbs	163
Figure 5.95: Hemophilia Market Share by Company, 2016	164
Figure 6.1: Core Therapy Areas for Biosimilars	178
Figure 6.2: Biosimilars' Market by Geography/Country	179
Figure 6.3: Top Players in Biosimilars Market	184
Figure 6.4: Number of Biologics per Indication to Go Off Patent prior to 2020	187
Figure 6.5: Patent Expiration of leading mAbs	188
Figure 6.6: Biosimilar mAbs in Pipeline	189
Figure 6.7: Disease Indications for Biosimilar mAbs Currently in Clinical Trials	190
Figure 6.8: Global Leaders in Biosimilars, 2012	191
Figure 6.9: Projected Biosimilars Market Split (\$10 Billions) in 2015	192
Figure 6.10: The Exploding Global Biosimilars Market, 2012-2020	194
Figure 6.11: Estimated Value and Growth Rates for Biosimilars by Type, 2015	195
Figure 6.12: Global Spending (%) for Biosimilars by Drug Type (\$2.5 Billion), 2015	196
Figure 6.13: Biosimilars Market in the U.S., 2011-2019	204
Figure 6.14: HGH Biosimilars in the U.S. Market, June 2009-September 2012	205
Figure 6.15: Projected U.S. Spend on 11 Specific Biologics, 2012-2024	206
Figure 6.16: Biosimilar Launchable Dates in the U.S., 2012-2022	208

Figure 6.17: Cumulative Worldwide Sales of Reference Products, 2012-2022	209
Figure 6.18: Geographic Distribution of Biosimilar Companies as of 2013	211
Figure 6.19: Number of Products by Country as of 2013	212
Figure 6.20: Biosimilars/Biobetters Companies by Size Range (Revenue \$ Billions) Worldwide, 2013	213
Figure 6.21: Biosimilars Approved in the E.U., 2012	215
Figure 6.22: Biosimilars Market in Europe and Japan, 2012-2019	216
Figure 6.23: Annual European Sales of Filgrastim Products, 2010-2012	217
Figure 6.24: Number of Scientific Advice from EMA by Biosimilars Firms	218
Figure 6.25: Biosimilars Penetration Rate (%) in Daily G-CSF Class Market, 2012	220
Figure 6.26: Revenue Forecast for Biosimilar Insulin Glargine in Major Seven Markets, 2009-2020	221
Figure 6.27: Revenue Forecast for Biosimilar HGH in the Major Seven Markets, 2009-2020	221
Figure 6.29: Revenue Forecast for Biosimilar IFN Beta Ia in the Major Seven Markets, 2009-2020	223
Figure 6.30: Revenue Forecast for Biosimilar Filgrastim in the Major Seven Markets, 2009-2020	223
Figure 6.31: Revenue Forecast for Biosimilar Epoetin Alpha in the Major Seven Markets, 2009-2020	224
Figure 6.32: Biosimilars Uptake Rates in Europe's Top Five Countries, 2012	225
Figure 6.33: Market for Biosimilars in China, 2012-2019	227
Figure 6.34: Biosimilar Market in India, 2008-2012	228
Figure A.2.1: Percent Change in Hospital Admissions and Office Visits, 2012	306
Figure A.2.2: Percent Population, Prescriptions and Per Capita Change in Prescriptions by Age	307
Figure A.2.3: Therapy Areas for Largest Positive and Negative Contribution to Growth	307
Figure A.2.4: U.S. National Respiratory Illness Estimates, 2010-2013	308
Figure A.2.5: Per Capita Spending Growth, 2002-2017	309
Figure A.2.6: Percent of Health Plan Members Ranked by Healthcare Spending	310
Figure A.2.7: Percent of Health Plan Members Healthcare Spending	311
Figure A.2.8: Components of Change in Total Spending (\$ Billion), 2011-2012	312
Figure A.2.9: Protected Brand Price Spending Growth, 2008-2012	313
Figure A.2.10: New Brand Spending (\$ Billions)	314
Figure A.2.11: Percent Share of Prescriptions, 2003-2012	314
Figure A.2.12: Comparison of Medicine Spending by Segment, 2012	315
Figure A.2.13: Significant Increase in Consumer-Driven Health Plans Enrollment, 2008-2012	315
Figure A.2.14: Average Patient Out-of-Pocket Costs by Plan Type, 2008-2012	316
Figure A.2.15: Average Annual Out-of-Pocket Costs for Deductibles, Co-Pay and Co-Insurance Spend	317
Figure A.2.16: Percent of Retail Dispensed Prescriptions by Out-of-Pocket Costs, 2012	318
Figure A.2.17: Percent of Retail Dispensed Prescriptions by Out-of-Pocket Costs	318
Figure A.2.18: New Molecular Entities Launched in the U.S., 2003-2012	319
Figure A.2.19: New Oncology NME Launches in the U.S., 2003-2012	320
Figure A.2.20: Spending in Leading Therapy Areas	324
Figure A.2.21: Oncology Spending by Area	325
Figure A.2.22: U.S. Market for Oncologics, 2008-2012	326
Figure A.2.23: U.S. Market for Rituxan, 2008-2012	326
Figure A.2.24: U.S. Market for Avastin, 2008-2012	327
Figure A.2.25: Mental Health Spending by Area, 2012	328
Figure A.2.26: U.S. Market for Mental Health Medicines, 2008-2012	329
Figure A.2.27: U.S. Market for Cymbalta, 2008-2012	330
Figure A.2.28: U.S. Market for Abilify, 2008-2012	331
Figure A.2.29: Respiratory Spending by Area, 2012	332
Figure A.2.30: U.S. Market for Respiratory Agents, 2008-2012	333
Figure A.2.31: U.S. Market for Advair Diskus, 2008-2012	334
Figure A.2.32: U.S. Market for Singulair, 2008-2012	334
Figure A.2.33: Spiriva HandiHaler, 2008-2012	335
Figure A.2.34: Antidiabetes Spending by Area, 2008-2012	336
Figure A.2.35: U.S. Market for Antidiabetics, 2008-2012	337
Figure A.2.36: U.S. Market for Januvia, 2008-2012	338
Figure A.2.37: U.S. Market for Lantus, 2008-2012	339
Figure A.2.38: U.S. Market for Lantus SoloSTAR, 2008-2012	340
Figure A.2.39: Pain Spending by Area, 2008-2012	340
Figure A.2.40: Pain Spending by Area, 2008-2012	341
Figure A.2.41: U.S. Market for Pain Management Drugs, 2008-2012	342

Figure A.2.42: U.S. Market for Medicines Used in Nervous System Disorders, 2008-2012	342
Figure A.2.43: U.S. Market for Oxycontin, 2008-2012	343
Figure A.2.44: U.S. Market for Lyrica, 2008-2012	344
Figure A.2.45: U.S. Market for Copaxone, 2008-2012	345
Figure A.2.46: U.S. Market for Lipid Regulators, 2008-2012	345
Figure A.2.47: U.S. Market for Crestor, 2008-2012	346
Figure A.2.48: U.S. Market for Autoimmune Drugs, 2008-2012	347
Figure A.2.49: U.S. Market for Humira, 2008-2012	348
Figure A.2.50: U.S. Market for Enbrel, 2008-2012	349
Figure A.2.51: U.S. Market for Remicade, 2008-2012	350
Figure A.2.52: U.S. Market for Medicines Used for Multiple Sclerosis, 2008-2012	351
Figure A.2.53: U.S. Market for Antiulcerants, 2008-2012	351
Figure A.2.54: U.S. Market for Nexium, 2008-2012	352
Figure A.2.55: U.S. Market for Neulasta, 2008-2012	353
Figure A.2.56: U.S. Market for Epogen, 2008-2012	354
Figure A.2.57: U.S. Market for Platelet Aggregation Inhibitors, 2008-2012	354
Figure A.2.58: U.S. Market for Plavix, 2008-2012	355
Figure A.2.59: U.S. Market for HIV Antivirals, 2008-2012	356
Figure A.2.60: U.S. Market for Atripla, 2008-2012	357
Figure A.2.61: U.S. Market for Truvada, 2008-2012	358
Figure A.2.62: U.S. Market for Antibacterials, 2008-2012	358
Figure A.2.63: U.S. Market for Antihypertensives, Plain & Combo, 2008-2012	359
Figure A.2.64: U.S. Market for Diovan, 2008-2012	360
Figure A.2.65: U.S. Market for ADHD, 2008-2012	361
Figure A.2.66: U.S. Market for Vaccines (Pure, Comb and Others), 2008-2012	362
Figure A.2.67: U.S. Market for Systemic Hormonal Contraceptives, 2008-2012	362
Figure A.2.68: Treated Patients in Selected Therapies in the U.S., 2012	363
Figure A.4.1: Ranking of Asian Territories across All Factors	374
Figure A.4.2: Cost Ranking of Asian Territories	375
Figure A.4.3: Market Opportunity Ranking of Asian Territories	376
Figure A.5.1: Steady Increase of Biologics as a Share of Total FDA Approval	382
Figure A.5.2: Proportion of Health Insurers with Plans for Implementing Novel Contracting Models	383
Figure A.5.3: Insurer Expectations of Evidence from Manufacturer for Formulary Placement	384
Figure A.5.4: Data on Total U.S. Prescription Drug Spending	385
Figure A.5.5: Need for Aligned Efforts of Providers, Payers and Patients for Better Patient Outcomes	388
Figure A.5.6: Number of Companion Diagnostics Partnerships with Pharma	389
Figure A.5.7: Payer's Perceived Barriers to Novel Contracting Practices	390
Figure A.5.8: Current and Future State of Data Conversions and Analysis	392
Figure A.5.9: Sources of Influence for Formulary Coverage and Decision Making	393
Figure A.6.1: Medical Cost Trend, 2010-2013	394
Figure A.6.2: Private Health Insurance Benefits by Spending Category	395
Figure A.6.3: Percent of U.S. Patients Seeking Treatment in Retail Clinics	396
Figure A.6.4: Surgical Cosmetic Procedures in the U.S.	397
Figure A.6.5: Increase in High-Cost Insurance Claims	398
Figure A.6.6: Percentage of Individuals with Employer-Sponsored Coverage in a High-Deductible Plan with a Savings Option	399
Figure A.6.7: Percentage of Consumers Delaying Care Because of Cost	399

INDEX OF TABLES

Table 2.1: R&D Spending by Top 20 Companies, 2012-2018	24
Table 2.2: Top 20 Most Valuable Pharmaceutical R&D projects, 2018	25
Table 2.3: Most Valuable R&D Projects (Ranked by NPV), May 2012 and Current	26
Table 2.4: FDA Approval Count (NMEs & Biologics) vs. Fifth Year after Launch U.S. Product Sales	26
Table 2.5: Top Ten NMEs of 2012 Ranked by U.S. Consensus Sales in 2017	27
Table 2.6: Increasing Demand for Pharmaceuticals in Emerging Markets	29
Table 2.7: Top Ten Global Pharmaceutical Firms, 2011-2012	32
Table 2.8: Top Ten Pharmaceuticals by Sales in 2012	33

Table 2.9: Worldwide Prescription and OTC Sales by Therapy Area in 2018	34
Table 2.10: Top Ten Companies in Global Oncology Sales, 2012-2018	35
Table 2.11: Top Five Oncology Product Sales, 2018	36
Table 2.12: Top Ten Companies and Global Antidiabetic Sales, 2012-2018	36
Table 2.13: Top Five Anti-Diabetic Products, 2018	37
Table 2.14: Top Ten Companies and Global Anti-Rheumatic Sales, 2012-2018	37
Table 2.15: Top Five Anti-Rheumatic Products, 2012-2018	38
Table 2.16: Top Ten Companies and Total Global Vaccine Sales, 2012-2018	38
Table 2.17: Top Five Vaccine Products, 2018	39
Table 2.18: Top Ten Companies and Total Global Anti-Viral Sales, 2012-2018	39
Table 2.19: Top Five Anti-Viral Products, 2018	40
Table 2.20: Top 50 Global Pharmaceutical Brands in 2018	40
Table 2.21: M&A Transactions in 2012	42
Table 2.22: U.S. Prescription Drug Sales by Top 20 Companies, 2010-2012	46
Table 2.23: Top 50 Pharmaceutical Products in the U.S., 2012	47
Table 2.24: Top 50 Pharmaceutical Brands in the U.S. in 2018	48
Table 2.25: Prescription Drug Sales in Europe by Top 20 Companies, 2010-2012	51
Table 2.26: Prescription Drug Sales in Japan by the Top 20 Companies, 2010-2012	54
Table 2.27: Regional Prescription Drug Sales in the U.S., Europe and Japan (Top 20 Companies), 2012	57
Table 3.1: Patent Expiries by Country and Year, 2011-2015	61
Table 3.2: Top 25 Companies by R&D Pipeline Size, 2012	65
Table 3.3: Top 25 Therapeutic Categories in R&D, 2011-2012	68
Table 3.4: Top 25 Individual Diseases in the R&D Pipeline, 2012	69
Table 3.5: Top 20 Mechanism of Action in 2012 R&D Pipeline	70
Table 3.6: Top 25 Drug Protein Targets in 2012 R&D Pipeline	71
Table 4.1: Top 20 Companies in Global Generics Sales, 2012	78
Table 5.1: Number of Biologics Available in the Global Market	82
Table 5.2: Global Sales of Top 12 Biologics (\$67 Billion), 2012	91
Table 5.3: Patent Protection for Roche's Biologics	91
Table 5.4: Humira's Revenues, Growth Rate and Market Share, 2010-2015	97
Table 5.6: Humira's Revenues, Growth Rate and Market Share, 2016-2022	97
Table 5.7: Top U.S. Biotech Companies Ranked by Revenue, 2011-2012	141
Table 5.8: Sales of Neulasta/Neupogen, 2010-2012	142
Table 5.9: U.S. Biotechnology at a Glance, 2011-2012	146
Table 5.10: R&D Investment by the Top Ten Biotech Companies in the U.S., 2010-2012	147
Table 5.11: Cost of Commonly Used Biologics in the U.S.	158
Table 5.12: Biologics Used for Treating Rheumatoid Arthritis	159
Table 5.13: Biologics and Their Mode of Administration for Arthritis Patients	160
Table 5.14: Cost Comparison of Arthritis Biologics	160
Table 5.15: Total Hemophilia Market, 2011-2016	164
Table 5.16: Hemophilia A (Factor VIII) and von Willebrand Disease, Sales from Marketed Products and Late-Stage Pipeline, 2012-2016	165
Table 5.17: Hemophilia B, Marketed Products and Late Stage Pipeline, 2012-2016	166
Table 5.18: The Inhibitor Market: Products and Pipeline	167
Table 6.1: Definitions of Biosimilar Products	171
Table 6.2: Biosimilar Pipeline in the U.S.	182
Table 6.3: Other Key Players in Biosimilars Space	186
Table 6.4: Patent Expiration for Major Biologics	187
Table 6.5: Development Status of mAbs Biosimilars	190
Table 6.6: Generic Companies Active in Biosimilar Space	193
Table 6.7: Biosimilars Pipeline by Class, 2012	193
Table 6.8: Market Exclusivity Period for Specific Biologics in the U.S.	199
Table 6.9: Selected Biosimilars and Biobetters Currently in Development as of 2013	210
Table 6.10: Companies with the Largest Biosimilar Portfolios as of 2013	213
Table 6.11: Biosimilars Approved by the E.U.	219
Table 6.12: Native mAbs Developers in China	227
Table 6.13: Domestic Biosimilar Developers in India	229
Table 6.14: Celltrion's Biosimilar Pipeline	229

Table 6.15: Summary of Publicly Announced Biosimilar Product Transactions Through 2012	233
Table 7.1: Selected Generics from Apotex	249
Table 7.2: AstraZeneca's Development Projects	251
Table 7.3: Patent Expiries of AstraZeneca's Key Marketed Products	251
Table 7.4: Plasma Derivatives from Bharat Serums and Vaccines Limited	253
Table 7.5: Biogen Idec's Product Pipeline	256
Table 7.6: Bristol's Key Products	258
Table 7.7: Reddy's Product List	262
Table 7.8: New Products Launched by Richter in Hungary	263
Table 7.9: New Products Launched by Richter in Central and Eastern Europe	264
Table 7.10: GSK's Prescription Medicines	265
Table 7.11: Key Products from Intas	268
Table 7.12: Merck's Key Pharmaceutical Products	269
Table 7.13: Pfizer's Major Biopharmaceutical Products	273
Table A.1.1: Biologic Medicines by Development Phase, 2013	281
Table A.2.1: List of NMEs Launched in 2012	321
Table A.2.2: Other NMEs Launched in 2012	322
Table A.2.3: Top Therapeutic Classes by Prescriptions, 2008-2012	364
Table A.2.4: Top Medicines by Prescriptions in the U.S., 2008-2012	365
Table A.3.1: Pharmaceutical Deals in 2012	367

1. Overview

1.1 Statement of Report

The pharmaceutical and biopharmaceutical industries continue to be energetic, lucrative and growing segments, regardless of the slow ongoing recovery from worldwide economic problems. There are more than [REDACTED] therapeutics in R&D, both drugs (chemical substance pharmaceuticals) and biopharmaceuticals (biotechnology-derived pharmaceuticals), with [REDACTED] ongoing clinical trials. Among these, approximately [REDACTED]% or more than [REDACTED] to [REDACTED] candidate products in R&D are biopharmaceuticals. This is a significant increase from as short as [REDACTED] years ago and indicates a basic shift in the pharmaceutical industry from small molecule drugs to biopharmaceuticals for new, innovative and profitable products. This TriMark report is mainly focused on the development and market potentials of biopharmaceuticals (biologics) and biosimilar drugs.

Biopharmaceuticals are being developed by an ever-increasing number of companies, including Big Pharma and even generic drug companies, with many of these focused on developing biosimilars. As biopharmaceuticals are becoming important part of the pharmaceutical industry, several new firms are entering the field and existing manufacturers are expanding their bioprocessing capacity. While focused on cost-saving efforts, these biopharmaceutical firms are outsourcing many support and even critical tasks. The recent global economic downturn has done very little damage to the biopharmaceutical industry and there are now clear signs of real growth. Companies have started spending more in R&D and also are increasing their bioprocessing capacity.

The global market for biopharmaceuticals is now nearly \$[REDACTED]; growing at about [REDACTED]% annually, definitely a very healthy rate. Launching of new products continue to support global market growth. The global market for recombinant protein therapeutics has exceeded the \$[REDACTED]/year landmark. The impressive high growth rate in biopharmaceutical markets will continue to bring in investment in the industry, including at the expense of traditional small molecule drug developers. Larger companies are now paying attention to in-house manufacturing capacity instead of outsourcing their R&D and other tasks.

Biopharmaceutical firms in many emerging economies that are serving their domestic, regional or lesser-regulated international markets are witnessing rapid growth. Despite the fact that majority of drugs (mostly generics) are now being manufactured in China and India, no Asian country yet manufactures biopharmaceutical products marketed in the U.S. or the European Union (E.U.). South Korea is another country that has the potential to become one of the manufacturing centers of biopharmaceuticals. Nowadays, Ireland has become the choice for large companies to build their biopharmaceutical manufacturing facilities.

1.2 About this Report

This study first describes the existing and projected markets for pharmaceuticals in general, encompassing regional and country-wise trends. The data provided give an insight into the market potential of pharmaceutical drugs in general and also the sales revenues generated by specific drugs used in different therapeutic areas. Drugs losing patent protection from [REDACTED] to [REDACTED] are listed their volume of business in the past few years also have been shown. The predominance of generic drugs in the emerging markets is well documented with the support of graphs and tables. The report illustrates how the generics are gaining a foothold in the under-penetrated markets such as Japan and Western Europe with the assistance of government regulations and incentives. The report mainly discusses about the emergence of biologics and biosimilars and their potential role in shaping the future of global healthcare industry.

The main objectives of the analysis in this report are:

- To analyze the changing dynamics of the pharmaceutical market.
- To look into the ever increasing public healthcare expenditure that drives the growth of pharmaceutical market.
- To assess the potential global market for pharmaceutical drugs and the current market in different geographical regions.
- To identify the drugs losing patent protection until [REDACTED] by country.

- To estimate the loss of big pharmaceutical firms due to patent expiries.
- To evaluate the decline in market share for branded drugs by geography.
- To study the global and regional markets for generics.
- To analyze the utilization rates for generics in various countries.
- To identify the top ten generic markets in the world.
- To assess the savings from generics use in the U.S.
- To identify the therapeutic areas that lead in generics savings.
- To identify the top ■ generic launches from ■ to ■.
- To estimate the global market for biologics.
- To identify the largest selling biologics.
- To analyze the large number of clinical trials involving biologics.
- To identify the leading manufacturing firms in biologics.
- To estimate the uptake of biologics by region/country in ■.
- To find the number of biosimilars approved in the E.U.
- To estimate the global and regional markets for biosimilars.
- To identify the centers of fast-growing biosimilars markets.

By purchasing this study, the reader will gain:

- An understanding of the regulatory pathways for branded pharmaceuticals and the biologics.
- An understanding of how the generics and biosimilars have successfully eroded the strong and unassailable positions enjoyed by the branded and biologics.
- An insight into the number of patent expiries in the domain of branded and biologics drugs and the consequent wave of opportunities for generics and biosimilars in the next ten years.
- An understanding of how the pharmaceutical firms are changing their business strategies by shifting their focus from developed markets to the emerging markets in order to retain their share in pharmaceutical business.
- An insight into the vast number of biologics in clinical trials and their applications in various clinical needs.

Key questions answered in this review are:

- Does the pharmaceutical industry possess the required level of immunity to withstand the onslaught of economic vagaries around the globe?
- What are the growth rates for the pharmaceutical market in North America, Japan, Western Europe, Latin America, Eastern Europe and Asia/Africa regions?
- What are the comparative growth rates for branded and generic drugs?
- What is the average price difference between branded and generic drugs in the U.S. and European markets?
- What is the projected market value for branded, generic, biologic and biosimilar drugs from ■ to ■ in different geographic regions and countries?
- Which are the leading manufacturing companies of branded, generic, biologic and biosimilar drugs, what share do they have in the global and regional markets?
- Which are the leading MNC companies operating in the two largest emerging markets; China and India?

1.3 Scope of the Report

This analysis mainly dwells on the global and regional markets for branded, generic, biologic and biosimilar drugs to emphasize generic and biosimilars are gaining market shares from branded and biologic drugs. The report discusses in detail how the patent expirations of a large number of branded and biologic drugs are paving the way for the ascendancy of generics and biosimilars in the global pharmaceutical landscape. The report does not discuss the profiles of all the participating firms in the pharmaceutical industry, but focuses only on the leading manufacturing firms which control the market globally with a larger share in the market. The reader can consult other TriMark Publication reports on the TriMark website to gain insight into other pharmaceutical sub-segments.

1.4 Objectives

Between 2008 and 2012, the pharmaceutical industry is facing the largest and most unexpected loss of revenue in history. During this period, about 15% of the top 100 blockbuster drugs are losing patent protection, causing losses for almost all the big pharmaceutical firms. This period provides unlimited opportunities for the generics to flood the market and garner a larger share in almost all the geographical segments of the market. Lipitor, Plavix, Singulair, Seroquel, Actos, Lexapro and Zyprexa lost the patent protection in 2012 and 2013 and other drugs will be losing the protection between 2014 and 2015.

Biologics are medicines of large complex molecules manufactured through cell culture recombinant DNA technology and comprise recombinant insulin, growth hormone and monoclonal antibodies for treating conditions such as cancer and autoimmunity. The manufacture, testing and quality control of biologics is an expensive process, and therefore they represent some of the most expensive pharmaceutical products. However, they represented 15% of global pharmaceutical spending, with sales value reaching about \$100 billion in 2012. Just as generics are to branded drugs, biosimilars are to biologics and adoption of biosimilars can effectively bring down the healthcare expenditure significantly.

Currently, the biosimilars market is relatively small focused only on a small number of diseases; but the market has been predicted to grow substantially particularly in the U.S. and the developing economies such as Brazil and South Korea. The U.S. is an important market representing about 40% of the potential market that biosimilars firms need to tap into in the coming years. Faced with patent expiries, the pharmaceutical industry, generics and biotech firms are turning, for future revenues, to biosimilars. Thus, this report discusses in detail, the various strategies adopted by the pharmaceutical manufacturing firms to retain their market shares, expand their sphere of influence in different market segments and excel in their performance.

1.5 Methodology

The author of this report is a retired college professor with more than three decades of experience in teaching, biochemistry, biochemical pharmacology, biotechnology, genetics and cell biology. He also has six years of experience in editing healthcare related market research reports. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, sources of information include non-governmental organizations (NGOs), such as the World Health Organization (WHO), and governmental entities like the U.S. Department of Health and Human Services (HHS), and U.S. federal agencies such as the National Cancer Institute (NCI), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the American Cancer Society (ACS) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used. Some of the most valuable data were sourced from the most recently published report "World Preview 2013, Outlook to 2015," by EvaluatePharma in June 2012. These data offer insight into the 2012 sales of different classes of drugs including the top-selling biologics. Data on monoclonal antibodies (mAb) were sourced from articles from Antibody Society.

Some statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission, or the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publication's Report, Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners from the industry being analyzed.

1.6 Executive Summary

The biopharmaceutical market keeps on expanding. There are now over ██████ therapeutic candidates in R&D and about █% of them are biopharmaceuticals. There is a visible trend of a shift towards biopharmaceuticals, with the large traditionally small molecule drug-oriented Big Pharma firms shifting their focus on biopharmaceuticals. For these firms, biopharmaceuticals offer higher sales and profits per sale. The global biopharmaceutical market is now about \$█████ per year. The biopharmaceutical market continues to increase globally, with a CAGR of about █% to █%, making biopharmaceuticals a fairly recession-proof, growing and profitable industry. Biotech drugs are anticipated to grow two to three times faster than the pharmaceutical market as a whole. Industry experts have estimated that there will be \$█████ in patent expiries of biologic drugs by █████, and █% of today's biotech drugs will be off-patent by █████. Sensing the market potential of biologics the larger global companies have declared programs to produce innovative drugs, biosimilars or follow-on biologics in all the major classes. Totally, █████ biologic drugs are available in the global market and among them █████ are proteins, █████ are antibodies and █████ are vaccines. Protein-based drugs are a fast growing class on the pharmaceutical market, with thousands of candidates in development. █████ of the top █████ prescription drugs in █████ were biologics. AbbVie's Humira (monoclonal antibody \$█████), Amgen's Enbrel (monoclonal antibody \$█████), Johnson & Johnson/Merck's Remicade (monoclonal antibody \$█████), Sanofi-Aventis' Lantus (long-acting basal insulin \$█████), and IDEC's MabThera (chimeric monoclonal antibody \$█████) took the first █████ places in the global prescription drugs market.

The global demand for recombinant proteins now exceeds \$ [REDACTED], and the industry reached this milestone two years ago in [REDACTED]. The market for recombinant monoclonal antibodies alone now stands at about \$ [REDACTED] and this represents approximately [REDACTED]% of the recombinant protein market and [REDACTED]% of total biopharmaceuticals market. The antibodies are usually very specific in their action, do not cause severe side effects and therefore well-received in the market. As many new monoclonal antibodies have reached the final stage of clinical trials that will be available for expanded indications. The earliest approved monoclonal antibody was muromonab-CD3 in [REDACTED]. Yet, the monoclonal antibodies became financially viable only after the approval of rituximab, palivizumab, infliximab and trastuzumab in the late [REDACTED]. Technologies in genetic engineering enabled the synthesis of these highly successful biologic products. Global market for monoclonal antibodies was about \$ [REDACTED] in [REDACTED] and it is predicted to grow at a CAGR of [REDACTED]% through [REDACTED]. These biologics are mostly used in cancer therapies and the leading players in this sector are Roche, Abbott, Johnson & Johnson and Merck.

Biosimilars have also increased in number and gained importance. Presently, the markets for approved biosimilars in Europe remain relatively small, only about \$ [REDACTED] for a [REDACTED] products, generally no more than [REDACTED]% of the market for the established reference product. The utilization and market penetration of biosimilars has been slowly increasing, as E.U. member and other countries have started implementing their own cost-controls and recommendations for biosimilars use, and as these countries' health care systems adopt these products. However, unlike Europe, utilization and market penetration by biosimilars in the U.S. is likely to be more rapid, upon approval, with private sector insurers expected to rapidly adopt and require use of biosimilars wherever possible. Therefore, it is reasonable to predict that biosimilars will have a global market of several billion dollars over the next few years. Many more companies are entering the biosimilars industry and all these firms are most likely to bring in many other new products. Thus, biosimilars will only be fracturing the markets for successful biopharmaceuticals coming off-patent.

As of April [REDACTED], there were more than [REDACTED] biopharmaceutical drugs cleared in the U.S. and European markets, including [REDACTED] recombinant proteins and [REDACTED] monoclonal antibodies. There were [REDACTED] biologics cleared in both the U.S. and Europe, including [REDACTED] recombinant proteins and [REDACTED] monoclonal antibodies. There are a minimum of [REDACTED] biologic drug candidates with FDA applications either pending or expected within coming months. The U.S. accounts for approximately [REDACTED] of global biopharmaceutical sales. Thus, U.S. sales of biologic drugs have been estimated to be in the range of \$ [REDACTED] to \$ [REDACTED] annually. The U.S. economy and health care system can afford to support adoption of new biopharmaceuticals. The same is not true for other major market countries, where cost-conscious centralized government control of pharmaceutical markets, e.g., U.K., can lead to reluctance to adopt certain biologics which are quite expensive. Growth in most of the rest of the world seems to be propelled more by overall economic improvement, including the development of a middle class, and other broad economic and social trends supporting improved health care in these countries. The most important class of biopharmaceuticals showing the fastest growth in market revenue is recombinant monoclonal antibodies. Monoclonal antibodies have become well-entrenched in the marketplace, having proven to be effective therapeutics candidates since the mid-[REDACTED]. Quite a large number of mAb products are blockbusters, with many of these used for cancer treatment.